Letter: The clinical course of patients with analgesic nephropathy.
Thirty-four patients with analgesic nephropathy were followed at intervals of 1 to 3 months with measurements of creatinine clearance and serum concentration of acetylsalicylic acid (ASA) for a total of 105 patient-years. Diagnostic criteria included total consumption of at least 2 kg of phenacetin and 3 kg of ASA, compatible tissue abnormality on biopsy and evidence of papillary necrosis on an intravenous pyelogram. Nephropathy was induced by the same compound analgesic containing ASA, pehnacetin, caffeine and codeine (APC&C) in 30. Phenacetin was removed from this preparation in 1970 and replaced by an approximately equal amount of ASA (ACC). Creatinine clearance remained unchanged or improved in 11 of 15 patients who stopped taking analgesics containing phenacetin or ASA and in 10 of 11 of those who continued to take the ACC preparation. In contrast, renal function deteriorated in seven of eight patients who continued to abuse APC&C analgesics. The results suggest that phenacetin is necessary for the major nephrotoxic effect of this APC&C combination, but that ASA is not absolved of some nephrotoxicity.
D000700:Analgesics / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D002110:Caffeine / Q000627:therapeutic use; D003061:Codeine / Q000009:adverse effects / Q000627:therapeutic use; D003404:Creatinine / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000378:metabolism; D010146:Pain / Q000188:drug therapy; D010615:Phenacetin / Q000009:adverse effects / Q000627:therapeutic use; D012459:Salicylates / Q000097:blood; D019966:Substance-Related Disorders / Q000150:complications
D000700:Analgesics; D012459:Salicylates; D002110:Caffeine; D003404:Creatinine; D010615:Phenacetin; D001241:Aspirin; D003061:Codeine